-
Critical ALS Legislation You Need to Know About
Critical ALS Legislation You Need to Know About As we near the end of ALS
-
Gene therapy ATA-200 shows positive early results for children with LGMDR5
An experimental gene therapy called ATA-200 has shown promising safety and efficacy results in an
-
Quest Podcast: The People Behind the People: Family Caregiving, Policy, and the Power of Showing Up
In this episode of the Quest Podcast, we chat with Nicole Lucas, a devoted family
-
MDA Ambassador Guest Blog: How to Find Community for Young People Living with Debilitating Diseases
Since her diagnosis with ALS at age 32, Gwen Petersen has poured her energy into
-
Monitoring Duchenne: Strategies for handling symptom changes
Living with Duchenne muscular dystrophy (DMD) means your loved one will need to adapt to
-
Dyne initiates global Phase 3 trial in Duchenne amenable to skipping exon 51, ahead of planned FDA submission for accelerated approval in the US
Dyne Therapeutics, which received early funding from CureDuchenne, is initiating a Phase 3 FORZETTO Trial
-
In my life with DMD, I want to keep paying it forward, one story at a time
This week, I found myself reflecting on how much my life has changed since I
-
CureDuchenne Announces Partnership with Tevard Biosciences to Advance Suppressor tRNA Therapy for the Treatment of Duchenne Muscular Dystrophy
Tevard Biosciences to present most recent data to Duchenne community for first time at CureDuchenne
-
Dyne Announces Phase 3 Trial of Z-Rostudirsen, Plans for Submitting Biologics License Application to FDA
Dyne Therapeutics today announced the initiation of the company’s Phase 3 FORZETTO trial of zeleciment
-
CureDuchenne Appoints Lidia Gardner, PhD, EMBA, as Vice President of Clinical and Medical Affairs to Advance Patient-Centered Care, Research, and Strategic Partnerships
NEWPORT BEACH, Calif., May 20, 2026 /PRNewswire/ — CureDuchenne, a global nonprofit committed to finding and funding a
